FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284028653> ?p ?o ?g. }

• W2284028653 abstract "A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapagliflozin compared with control (placebo or comparator treatment) with or without background glucose-lowering therapies. The analysis reported here aimed to characterise the CV profile of dapagliflozin in subgroups of patients in these 21 studies grouped by degree of CV risk, based on both baseline and in-study risk factors (including hypoglycaemic events), with a focus on major adverse CV events (MACE). Patients with type 2 diabetes, both overall and with different levels of CV risk, including CV disease (CVD) history, age and other CV risk factors, were analysed. A further analysis compared CV risk in patients who experienced a hypoglycaemic event prior to MACE and those who did not. Analyses were based on time to first event using a Cox proportional hazards model stratified by study comparing dapagliflozin versus control. In total, 9339 patients were included in this meta-analysis; 5936 patients received dapagliflozin 2.5–10 mg (6668 patient–years) and 3403 received control (3882 patient–years). Dapagliflozin is not associated with increased CV risk and results further suggest the potential for a beneficial effect both in the overall population [Hazard Ratio (HR) 0.77; 95 % CI (0.54, 1.10) for MACE] and in those with a history of CVD [HR 0.80 (0.53, 1.22)]. These findings were consistent in patients with varying degrees of CV risk, including age, number and type of CVD events in medical history and number of CV risk factors present. Furthermore, there was no increased risk of MACE in patients who experienced a hypoglycaemic event compared with those who did not. There was no suggestion of increased risk for MACE with dapagliflozin compared with control in any of the populations investigated. In addition, the results suggest the potential for a beneficial CV effect which is consistent with the multifactorial benefits on CV risk factors associated with sodium–glucose cotransporter-2 (SGLT2) inhibitors." @default.
• W2284028653 created "2016-06-24" @default.
• W2284028653 creator A5007149007 @default.
• W2284028653 creator A5031725659 @default.
• W2284028653 creator A5066064493 @default.
• W2284028653 creator A5083911432 @default.
• W2284028653 date "2016-02-19" @default.
• W2284028653 modified "2023-10-12" @default.
• W2284028653 title "Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis" @default.
• W2284028653 cites W1517491980 @default.
• W2284028653 cites W1523363225 @default.
• W2284028653 cites W1526927233 @default.
• W2284028653 cites W172609984 @default.
• W2284028653 cites W1953840628 @default.
• W2284028653 cites W1970736869 @default.
• W2284028653 cites W1973240292 @default.
• W2284028653 cites W2001991301 @default.
• W2284028653 cites W2007221722 @default.
• W2284028653 cites W2008443217 @default.
• W2284028653 cites W2015191704 @default.
• W2284028653 cites W2022119612 @default.
• W2284028653 cites W2027398852 @default.
• W2284028653 cites W2030192134 @default.
• W2284028653 cites W2033417941 @default.
• W2284028653 cites W2054361323 @default.
• W2284028653 cites W2064130493 @default.
• W2284028653 cites W2068907080 @default.
• W2284028653 cites W2069397244 @default.
• W2284028653 cites W2072040765 @default.
• W2284028653 cites W2076506641 @default.
• W2284028653 cites W2076573528 @default.
• W2284028653 cites W2077636750 @default.
• W2284028653 cites W2090816085 @default.
• W2284028653 cites W2091977092 @default.
• W2284028653 cites W2097995302 @default.
• W2284028653 cites W2101865653 @default.
• W2284028653 cites W2105892231 @default.
• W2284028653 cites W2106426335 @default.
• W2284028653 cites W2110333911 @default.
• W2284028653 cites W2110660701 @default.
• W2284028653 cites W2114250030 @default.
• W2284028653 cites W2114276479 @default.
• W2284028653 cites W2115653936 @default.
• W2284028653 cites W2117505171 @default.
• W2284028653 cites W2120649968 @default.
• W2284028653 cites W2122077393 @default.
• W2284028653 cites W2123984464 @default.
• W2284028653 cites W2124658554 @default.
• W2284028653 cites W2126919962 @default.
• W2284028653 cites W2127833912 @default.
• W2284028653 cites W2127854619 @default.
• W2284028653 cites W2139171405 @default.
• W2284028653 cites W2140887581 @default.
• W2284028653 cites W2142593697 @default.
• W2284028653 cites W2142830692 @default.
• W2284028653 cites W2147222003 @default.
• W2284028653 cites W2148513135 @default.
• W2284028653 cites W2150855258 @default.
• W2284028653 cites W2153839551 @default.
• W2284028653 cites W2158666727 @default.
• W2284028653 cites W2160088494 @default.
• W2284028653 cites W2166247199 @default.
• W2284028653 cites W2172193326 @default.
• W2284028653 cites W2182718273 @default.
• W2284028653 cites W2208793669 @default.
• W2284028653 cites W4244540230 @default.
• W2284028653 doi "https://doi.org/10.1186/s12933-016-0356-y" @default.
• W2284028653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4761166" @default.
• W2284028653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26895767" @default.
• W2284028653 hasPublicationYear "2016" @default.
• W2284028653 type Work @default.
• W2284028653 sameAs 2284028653 @default.
• W2284028653 citedByCount "146" @default.
• W2284028653 countsByYear W22840286532016 @default.
• W2284028653 countsByYear W22840286532017 @default.
• W2284028653 countsByYear W22840286532018 @default.
• W2284028653 countsByYear W22840286532019 @default.
• W2284028653 countsByYear W22840286532020 @default.
• W2284028653 countsByYear W22840286532021 @default.
• W2284028653 countsByYear W22840286532022 @default.
• W2284028653 countsByYear W22840286532023 @default.
• W2284028653 crossrefType "journal-article" @default.
• W2284028653 hasAuthorship W2284028653A5007149007 @default.
• W2284028653 hasAuthorship W2284028653A5031725659 @default.
• W2284028653 hasAuthorship W2284028653A5066064493 @default.
• W2284028653 hasAuthorship W2284028653A5083911432 @default.
• W2284028653 hasBestOaLocation W22840286531 @default.
• W2284028653 hasConcept C126322002 @default.
• W2284028653 hasConcept C134018914 @default.
• W2284028653 hasConcept C2777180221 @default.
• W2284028653 hasConcept C2777422806 @default.
• W2284028653 hasConcept C555175668 @default.
• W2284028653 hasConcept C555293320 @default.
• W2284028653 hasConcept C71924100 @default.
• W2284028653 hasConcept C95190672 @default.
• W2284028653 hasConceptScore W2284028653C126322002 @default.
• W2284028653 hasConceptScore W2284028653C134018914 @default.
• W2284028653 hasConceptScore W2284028653C2777180221 @default.
• W2284028653 hasConceptScore W2284028653C2777422806 @default.
• W2284028653 hasConceptScore W2284028653C555175668 @default.

• next